<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548122" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548122/" /><meta name="ncbi_pagename" content="Prochlorperazine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Prochlorperazine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Prochlorperazine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/07/01" /><meta name="citation_pmid" content="31643452" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548122/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Prochlorperazine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/07/01" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548122/" /><meta name="description" content="Prochlorperazine is a phenothiazine used primarily as an antiemetic agent. In rare instances, prochlorperazine can cause clinically apparent acute and chronic cholestatic liver injury." /><meta name="og:title" content="Prochlorperazine" /><meta name="og:type" content="book" /><meta name="og:description" content="Prochlorperazine is a phenothiazine used primarily as an antiemetic agent. In rare instances, prochlorperazine can cause clinically apparent acute and chronic cholestatic liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548122/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Prochlorperazine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548122/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE886A8B046733B100000000069701E0.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548122_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548122_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Procarbazine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Progestins/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548122_"><span class="title" itemprop="name">Prochlorperazine</span></h1><p class="small">Last Update: <span itemprop="dateModified">July 1, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Prochlorperazine.OVERVIEW"><h2 id="_Prochlorperazine_OVERVIEW_">OVERVIEW</h2><div id="Prochlorperazine.Introduction"><h3>Introduction</h3><p>Prochlorperazine is a phenothiazine used primarily as an antiemetic agent. In rare instances, prochlorperazine can cause clinically apparent acute and chronic cholestatic liver injury.</p></div><div id="Prochlorperazine.Background"><h3>Background</h3><p>Prochlorperazine (proe" klor per' a zeen) is a tricyclic aliphatic phenothiazine which acts by postsynaptic inhibition of dopamine receptors. Prochlorperazine has other peripheral and central nervous system effects, producing both alpha adrenergic stimulation and blocking histamine- and serotonin-mediated effects. Prochlorperazine is indicated primarily for the therapy of nausea and vomiting. Prochlorperazine also has antianxiety and antipsychotic effects, but is used less commonly for these indications compared to the major phenothiazines such as chlorpromazine, fluphenazine, perphenazine, thioridazine and trifluoperazine. Prochlorperazine was approved for use in the United States in 1956 and is still widely used in therapy of nausea and vomiting. Prochlorperazine is available in generic forms as tablets of 5, 10 and 25 mg, in long acting capsules of 15 mg, as an oral solution of 5 mg/ 5 mL, as suppositories of 2.5, 5 and 25 mg, and in parenteral forms. Prochlorperazine is also available under the brand names of Compazine and Compro. Typical doses for nausea are 5 to 10 mg three to four times daily. Common side effects are similar to other phenothiazines and include drowsiness, dizziness, headache, blurred vision, dry mouth, constipation, tremor, restlessness, muscle spasms and weight gain. Rare but potentially severe adverse events (which apply to most antipsychotic agents) include an increased risk for death in the elderly with dementia-related psychosis, neuroleptic malignant syndrome, tardive dyskinesia and orthostatic hypotension.</p></div><div id="Prochlorperazine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p><a class="def" href="/books/n/livertox/glossary/def-item/glossary.liver-test-abnormalities/">Liver test abnormalities</a> are uncommon during prochlorperazine therapy, perhaps because it is rarely given long term or in high doses chronically. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aminotransferase/">Aminotransferase</a> elevations can occur during therapy, but they are usually mild, asymptomatic and transient and reversible even with continuation of medication. Rare instances of clinically apparent acute liver injury have been reported due to prochlorperazine which resemble the cholestatic liver injury associated with chlorpromazine. The onset of jaundice is usually within 1 to 4 weeks, and the pattern of serum enzyme elevations is typically cholestatic or mixed. Immunoallergic features (fever and eosinophilia) occur in some cases, but they are usually mild and self-limited; autoantibodies are rare. Liver biopsy typically shows a cholestatic hepatitis. Importantly, prochlorperazine jaundice can be prolonged and has been associated with rare cases of vanishing bile duct syndrome (Case 1) that can be fatal or ultimately require liver transplantation.</p><p>Likelihood score: B (uncommon but likely cause of clinically apparent liver injury).</p></div><div id="Prochlorperazine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which prochlorperazine causes serum aminotransferase elevations is not known but is likely shared with other phenothiazines. Several features of the clinical presentation of prochlorperazine hepatotoxicity (short latency period, fever, eosinophilia) suggest a hypersensitivity reaction, and rechallenge typically causes a rapid recurrence of injury. Prochlorperazine is extensively metabolized by the liver via sulfoxidation and oxidation, and some instances of serum aminotransferase elevations as well as more clinically apparent liver injury may be caused by production of a toxic intermediate of its metabolism.</p></div><div id="Prochlorperazine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that occur on prochlorperazine therapy are usually transient and do not require dose modification or discontinuation of therapy. The acute cholestatic hepatitis caused by prochlorperazine is typically self-limited and benign but should prompt immediate discontinuation. A small proportion of cases are followed by prolonged jaundice and cholestasis and features of vanishing bile duct syndrome. Many patients with chronic cholestasis eventually improve, but they may have persistent enzyme elevations and biliary cirrhosis. Fatalities from prochlorperazine jaundice have been reported. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.rechallenge/">Rechallenge</a> with phenothiazines usually causes a prompt recurrence of the liver injury and should be avoided.</p><p>Drug Class: Gastrointestinal Agents; <a href="/books/n/livertox/AntipsychoticAgents/">Antipsychotic Agents</a></p><p>Other Drugs in the Subclass, Phenothiazines: <a href="/books/n/livertox/Chlorpromazine/">Chlorpromazine</a>, <a href="/books/n/livertox/Fluphenazine/">Fluphenazine</a>, <a href="/books/n/livertox/Perphenazine/">Perphenazine</a>, <a href="/books/n/livertox/Thioridazine/">Thioridazine</a>, <a href="/books/n/livertox/Trifluoperazine/">Trifluoperazine</a></p></div></div><div id="Prochlorperazine.CASE_REPORT"><h2 id="_Prochlorperazine_CASE_REPORT_">CASE REPORT</h2><div id="Prochlorperazine.Case_1_Prolonged_choles"><h3>Case 1. Prolonged cholestatic liver injury due to prochlorperazine.(<a class="bk_pop" href="#Prochlorperazine.REF.1">1</a>)</h3><p>A 68 year old man was treated with trimethoprim/sulfamethoxazole (800/400 mg three times daily) for one week and prochlorperazine (10 mg daily) for 4 weeks for suspected otitis media. A few weeks after stopping prochlorperazine, he developed jaundice and pruritus. When first seen, one month after stopping medications, serum bilirubin was 18.4 mg/dL, alkaline phosphatase was 1.5 times normal and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> was minimally elevated (Table). Tests for viral hepatitis and abdominal ultrasound were normal. After persistence of jaundice for 3 months, a liver biopsy was done which showed centrilobular cholestasis with minimal hepatocyte necrosis or portal inflammation. The intralobular bile ducts were normal. He continued to have jaundice and severe pruritus and developed skin hyperpigmentation. Tests for hepatitis B and mitochondrial antibody were negative. Endoscopic retrograde cholangiopancreatography was normal. Serum bilirubin levels peaked 4 months after presentation and then began to decline, not becoming normal until one year later. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.pruritus/">Pruritus</a> and hyperpigmentation also resolved, but serum alkaline phosphatase and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a> levels remained elevated. A repeat liver biopsy, done two years after onset and 9 months after resolution of jaundice and symptoms, showed minimal cholestasis but bridging hepatic fibrosis and paucity of intralobular bile ducts. Two-and-a-half years after onset, serum alkaline phosphatase levels were still abnormal but he had no symptoms.</p><div id="Prochlorperazine.Key_Points"><h4>Key Points</h4><div id="Prochlorperazine.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548122/table/Prochlorperazine.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Prochlorperazine.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Prochlorperazine.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Prochlorperazine.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prochlorperazine (10 mg daily for 4 weeks)</td></tr><tr><th id="hd_b_Prochlorperazine.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Prochlorperazine.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cholestatic</td></tr><tr><th id="hd_b_Prochlorperazine.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Prochlorperazine.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4+ (prolonged jaundice and hepatic fibrosis)</td></tr><tr><th id="hd_b_Prochlorperazine.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Prochlorperazine.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 weeks</td></tr><tr><th id="hd_b_Prochlorperazine.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Prochlorperazine.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incomplete after 2 years</td></tr><tr><th id="hd_b_Prochlorperazine.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Prochlorperazine.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Trimethoprim/sulfamethoxazole</td></tr></tbody></table></div></div></div><div id="Prochlorperazine.Laboratory_Values"><h4>Laboratory Values</h4><div id="Prochlorperazine.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548122/table/Prochlorperazine.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Prochlorperazine.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_Prochlorperazine.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Prochlorperazine.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Prochlorperazine.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a>*<br />(U/L)</th><th id="hd_h_Prochlorperazine.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P*<br />(U/L)</th><th id="hd_h_Prochlorperazine.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>*<br />(mg/dL)</th><th id="hd_h_Prochlorperazine.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_Prochlorperazine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Prochlorperazine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Prochlorperazine.Td_1_1_1_3 hd_h_Prochlorperazine.Td_1_1_1_4 hd_h_Prochlorperazine.Td_1_1_1_5 hd_h_Prochlorperazine.Td_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Chlorpromazine (50 mg daily) given for nausea for 4 weeks</td></tr><tr><td headers="hd_h_Prochlorperazine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 month</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">49</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">116</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18.4</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Prochlorperazine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Prochlorperazine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 months</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">210</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">26.2</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Biopsy #1</td></tr><tr><td headers="hd_h_Prochlorperazine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Prochlorperazine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 months</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">88</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">219</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">19.3</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ERCP normal</td></tr><tr><td headers="hd_h_Prochlorperazine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Prochlorperazine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 months</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">85</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">365</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11.2</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Prochlorperazine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Prochlorperazine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 months</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">65</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">430</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.6</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Prochlorperazine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 year</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 months</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">60</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">410</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.5</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Prochlorperazine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 years</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22 months</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">85</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">445</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.0</td><td headers="hd_h_Prochlorperazine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Biopsy #2</td></tr><tr><td headers="hd_h_Prochlorperazine.Td_1_1_1_1 hd_h_Prochlorperazine.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Prochlorperazine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;42</b></td><td headers="hd_h_Prochlorperazine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;90</b></td><td headers="hd_h_Prochlorperazine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Prochlorperazine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>* </dt><dd><div id="Prochlorperazine.TF.d.1"><p class="no_margin">Some values estimated from Figure 1 and bilirubin converted from &#x003bc;mol/L to mg/dL.</p></div></dd></dl></div></div></div></div><div id="Prochlorperazine.Comment"><h4>Comment</h4><p>A typical example of the evolution of an acute cholestatic hepatitis to prolonged cholestasis and vanishing bile duct syndrome. The patient eventually improved and was asymptomatic, but alkaline phosphatase levels were persistently elevated and liver biopsy showed paucity of intralobular bile ducts and bridging hepatic fibrosis. Not all cases of vanishing bile duct syndrome progress to hepatic failure and eventual clinical improvement is common. Long term follow up on such cases usually demonstrates well compensated and nonprogressive cirrhosis and persistence of mild elevations in serum alkaline phosphatase.</p></div></div></div><div id="Prochlorperazine.PRODUCT_INFORMATION"><h2 id="_Prochlorperazine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Prochlorperazine &#x02013; Generic, Compazine&#x000ae;, Compro&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Gastrointestinal Agents; Antipsychotic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Prochlorperazine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Prochlorperazine.CHEMICAL_FORMULA_AND_ST"><h2 id="_Prochlorperazine_CHEMICAL_FORMULA_AND_ST_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Prochlorperazine.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548122/table/Prochlorperazine.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Prochlorperazine.Te_lrgtbl__"><table><thead><tr><th id="hd_h_Prochlorperazine.Te_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Prochlorperazine.Te_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Prochlorperazine.Te_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Prochlorperazine.Te_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Prochlorperazine.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prochlorperazine</td><td headers="hd_h_Prochlorperazine.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971659" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">58-38-8</a></td><td headers="hd_h_Prochlorperazine.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C20-H24-Cl-N3-S</td><td headers="hd_h_Prochlorperazine.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971659" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134971659" alt="image 134971659 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Prochlorperazine.CITED_REFERENCE"><h2 id="_Prochlorperazine_CITED_REFERENCE_">CITED REFERENCE</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Prochlorperazine.REF.1">Lok AS, Ng IO. Prochlorperazine-induced chronic cholestasis. <span><span class="ref-journal">J Hepatol. </span>1988;<span class="ref-vol">6</span>:369–73.</span> [<a href="/pubmed/3392386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3392386</span></a>]</div></dd></dl></div><div id="Prochlorperazine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Prochlorperazine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 01 July 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Prochlorperazine.REF.zimmerman.1999">Zimmerman HJ. Neuroleptic drugs. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 483-91.<div><i>(Expert review of hepatotoxicity of neuroleptic drugs including chlorpromazine published in 1999; several hundred cases of chlorpromazine jaundice have been reported, usually cholestatic, arising after 1-5 weeks, often with fever and eosinophilia, sometimes causing vanishing bile duct syndrome; other phenothiazines have only rarely been linked to liver injury, except for prochlorperazine).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.larry.2013">Larry D, Ripault MP. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 447-62.<div><i>(Review of phenothiazine hepatotoxicity mentions that liver enzyme elevations arise in up to 40% of patients, and hundreds of cases of chlorpromazine jaundice have been published with a frequency of 0.5-1%, onset within 2-5 weeks and usually presenting with acute cholestatic hepatitis with jaundice and pruritus and a prolonged course in 7%; other phenothiazines have been linked to liver injury similar to that of chlorpromazine, &#x0201c;but with a lower frequency&#x0201d; ).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.meyer.2018">Meyer JM. Pharmacotherapy of psychosis and mania. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 279-302.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.mechanic.1958.778">Mechanic RC, Meyers L. Chlorpromazine-type cholangitis; report of a case occurring after the administration of prochlorperazine. <span><span class="ref-journal">N Engl J Med. </span>1958;<span class="ref-vol">259</span>:778–80.</span> [<a href="/pubmed/13590448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13590448</span></a>]<div><i>(68 year old woman developed jaundice within 10 days of starting once daily prochlorperazine for nausea [peak bilirubin 26.8 mg/dL, AST 77 U/L, Alk P ~3 fold elevated], resolving slowly after stopping and undergoing laparotomy for suspected extrahepatic biliary obstruction).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.milne.1958.873">Milne HB, Berliner F. A clinical trial of Stemetil (prochlorperazine). <span><span class="ref-journal">J Ment Sci. </span>1958;<span class="ref-vol">104</span>:873–9.</span> [<a href="/pubmed/13588349" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13588349</span></a>]</div></li><li><div class="bk_ref" id="Prochlorperazine.REF.solomon.1959.840">Solomon FA Jr, Campagna FA. Jaundice due to prochlorperazine (Compazine). <span><span class="ref-journal">Am J Med. </span>1959;<span class="ref-vol">27</span>:840–3.</span> [<a href="/pubmed/13832654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13832654</span></a>]<div><i>(50 year old female developed jaundice 5 days after restarting prochlorperazine for nausea [bilirubin 19.2 mg/dL, Alk P ~20 times ULN]; biopsy showed intrahepatic cholestasis similar to chlorpromazine jaundice).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.crandell.1959.553">Crandell A, Ma JY. Jaundice precipitated by prochlorperazine (Compazine) in the treatment of alcoholic psychiatric disturbance. <span><span class="ref-journal">J Med Soc N J. </span>1959;<span class="ref-vol">56</span>:553–4.</span> [<a href="/pubmed/13812634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13812634</span></a>]<div><i>(26 year old man with alcoholism and tuberculosis developed fever and jaundice 24 days after starting a third course of prochlorperazine; serum enzyme and bilirubin levels were not provided).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.weinstein.1959.1663">Weinstein A, Alper B, Dade J. Cholestasis due to prochlorperazine. <span><span class="ref-journal">J Am Med Assoc. </span>1959;<span class="ref-vol">170</span>:1663–4.</span> [<a href="/pubmed/13672755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13672755</span></a>]<div><i>(49 year old woman developed nausea and pruritus 3 weeks after starting prochlorperazine [bilirubin 4.7 mg/dL, AST 75 U/L, Alk P ~2x ULN], biopsy showing intrahepatic cholestasis and resolving within 3-4 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.salde.1961.188">Salde H, Wallindr J. <span><span class="ref-journal">Svenska Lakartidningen. </span>1961;<span class="ref-vol">58</span>:188–97.</span> [Prochlorperazine for chronic psychosis] [<a href="/pubmed/13745578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13745578</span></a>]<div><i>(Analysis of 40 patients treated with prochlorperazine for psychosis; major side effects were sedation and extrapyramidal symptoms; no jaundice reported).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.mcqueen.1963.460">McQueen EG. Toxic effects of phenothiazine tranquillizers. <span><span class="ref-journal">N Z Med J. </span>1963;<span class="ref-vol">62</span>:460–2.</span> [<a href="/pubmed/14073060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14073060</span></a>]<div><i>(Review of the phenothiazines and their side effects; &#x0201c;Jaundice has occurred in about 1% of patients taking chlorpromazine, and also, although less frequently, in patients taking one of the more recently developed analogues&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.mcfarland.1963.284">McFarland RB. Fatal drug reaction associated with prochlorperazine (Compazine). Report of a case characterized by jaundice, thrombocytopenia, and agranulocytosis. <span><span class="ref-journal">Am J Clin Pathol. </span>1963;<span class="ref-vol">40</span>:284–90.</span> [<a href="/pubmed/14063694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14063694</span></a>]<div><i>(73 year old woman hospitalized for suspect myocardial infarction was given prochlorperazine and developed fever 31 days later with thrombocytopenia [bilirubin 2.8 mg/dL, AST 1480 U/L]; prochlorperazine was stopped, but she worsened and died of multiorgan failure 2 weeks later, autopsy showed centrolobular necrosis).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.cook.1965.175">Cook GC, Sherlock S. Jaundice and its relation to therapeutic agents. <span><span class="ref-journal">Lancet. </span>1965;<span class="ref-vol">1</span>:175–9.</span> [<a href="/pubmed/14238042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14238042</span></a>]<div><i>(Summary of cases of drug induced liver disease seen at Royal Free Hospital between 1959-65; 11 cases of acute liver failure including 3 due to iproniazid, 2 phenelzine, 2 phenoxypropazine, 1 prochlorperazine and 3 halogenated anesthetics; 20 cases of cholestatic hepatitis including 18 due to chlorpromazine, 1 perphenazine and 1 nitrofurantoin).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.walker.1966.631">Walker CO, Combes B. Biliary cirrhosis induced by chlorpromazine. <span><span class="ref-journal">Gastroenterology. </span>1966;<span class="ref-vol">51</span>:631–40.</span> [<a href="/pubmed/5926937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5926937</span></a>]<div><i>(Two patients, a 32 year old woman and a 31 year old man, developed persistent jaundice [&#x0003e;4 years], cholestasis and liver fibrosis 3 and 4 weeks after starting chlorpromazine; acute cholestatic hepatitis evolving into chronic form with biopsies showing cirrhosis and complications of portal hypertension).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF15">Case records of the Massachusetts General Hospital. Case 32-1967. <span><span class="ref-journal">N Engl J Med. </span>1967;<span class="ref-vol">277</span>:255–62.</span> [<a href="/pubmed/6029314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6029314</span></a>]<div><i>(86 year old woman with complicated course after cholecystectomy resulting in multiorgan failure; autopsy showing &#x0201c;toxic hepatitis&#x0201d; and prochlorperazine considered a possible cause).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.ishak.1972.283">Ishak KG, Irey NS. Hepatic injury associated with the phenothiazines. Clinicopathologic and follow-up study of 36 patients. <span><span class="ref-journal">Arch Pathol. </span>1972;<span class="ref-vol">93</span>:283–304.</span> [<a href="/pubmed/5017281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5017281</span></a>]<div><i>(Review of 36 liver biopsies of phenothiazine induced hepatotoxicity from the files of the Armed Forces Institute of Pathology; 33 due to chlorpromazine, 3 prochlorperazine; mean onset 15 days, eosinophilia in 73%, mean bilirubin 12.4 mg/dL, Alk P ~8 fold elevated, ALT 146 U/L; 6 [17%] had prolonged course for 10-16 months).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.d_ssing.1982.205">D&#x000f8;ssing M, Andreasen PB. Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs. <span><span class="ref-journal">Scand J Gastroenterol. </span>1982;<span class="ref-vol">17</span>:205–11.</span> [<a href="/pubmed/6982502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6982502</span></a>]<div><i>(Among 572 cases of drug induced liver disease seen between 1968-78 in Denmark, 51 were attributed to chlorpromazine [9%, ranking 2nd behind halothane], latency averaging 14 days [range 11-46]; 5 deaths; no other phenothiazines mentioned).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.kaplowitz.1986.826">Kaplowitz N, Aw TY, Simon FR, Stolz A. Drug-induced hepatotoxicity. <span><span class="ref-journal">Ann Intern Med. </span>1986;<span class="ref-vol">104</span>:826–39.</span> [<a href="/pubmed/3518564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3518564</span></a>]<div><i>(Review of drug induced hepatotoxicity including phenothiazine jaundice).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.munyon.1987.182">Munyon WH, Salo R, Briones DF. Cytotoxic effects of neuroleptic drugs. <span><span class="ref-journal">Psychopharmacology (Berl). </span>1987;<span class="ref-vol">91</span>:182–8.</span> [<a href="/pubmed/2883697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2883697</span></a>]<div><i>(In vitro assay for cytotoxicity of 8 neuroleptic drugs found that chlorpromazine was more toxic than haloperidol and loxapine, but similar to other phenothiazines).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.regal.1987.787">Regal RE, Bili JE, Glazer HM. Phenothiazine-induced cholestatic jaundice. <span><span class="ref-journal">Clin Pharm. </span>1987;<span class="ref-vol">6</span>:787–94.</span> [<a href="/pubmed/2905941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2905941</span></a>]<div><i>(Review of phenothiazine induced liver injury; cross sensitivity is rare &#x0201c;but does exist&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.lok.1988.369">Lok AS, Ng IO. Prochlorperazine-induced chronic cholestasis. <span><span class="ref-journal">J Hepatol. </span>1988;<span class="ref-vol">6</span>:369–73.</span> [<a href="/pubmed/3392386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3392386</span></a>]<div><i>(68 year old man developed jaundice 4 weeks after starting prochlorperazine [peak bilirubin 26 mg/dL, ALT 50-90 U/L, Alk P 120-500 U/L], jaundice and pruritus persisting for more than a year, but then gradual clinical improvement but with persistent enzyme elevations, and biopsy 22 months after onset showed fibrosis and paucity of bile ducts: Case 1).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.bach.1989.1303">Bach N, Thung SN, Schaffner F, Tobias H. Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate. <span><span class="ref-journal">Dig Dis Sci. </span>1989;<span class="ref-vol">34</span>:1303–7.</span> [<a href="/pubmed/2502367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2502367</span></a>]<div><i>(45 year old man developed fatigue and fever 12 days after starting chlorpromazine for hiccups [bilirubin 21.5 mg/dL, ALT 1312 U/L, Alk P 617 U/L], with persistent jaundice and pruritus for several years and eventual presence of cirrhosis and varices; paucity of bile ducts on biopsy).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.pillans.1996.315">Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years experience. <span><span class="ref-journal">N Z Med J. </span>1996;<span class="ref-vol">109</span>:315–9.</span> [<a href="/pubmed/8816722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8816722</span></a>]<div><i>(Over 21 year period in New Zealand, there were 943 official reports of liver injury involving 205 drugs; chlorpromazine was in the top 20 drugs implicated accounting for 2.7% of cases; prochlorperazine was cause of 4 cases, but other phenothiazines not mentioned).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.sabat_.2007.1401">Sabat&#x000e9; M, Ib&#x000e1;&#x000f1;ez L, P&#x000e9;rez E, Vidal X, Buti M, Xiol X, Mas A, et al.  Risk of acute liver injury associated with the use of drugs: a multicentre population survey. <span><span class="ref-journal">Aliment Pharmacol Ther. </span>2007;<span class="ref-vol">25</span>:1401–9.</span> [<a href="/pubmed/17539979" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17539979</span></a>]<div><i>(Among 126 cases of drug induced liver injury seen in Spain between 1993 and 2000, 3 were due to chlorpromazine with relative risk of 613: frequency of 261 per 100,000 person year exposures; no other phenothiazine mentioned).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.mindikoglu.2003.1338">Mindikoglu AL, Anantharaju A, Hartman GG, Li SD, Villanueva J, Van Thiel DH. Prochlorperazine-induced cholestasis in a patient with alpha-1 antitrypsin deficiency. <span><span class="ref-journal">Hepatogastroenterology. </span>2003;<span class="ref-vol">50</span>:1338–40.</span> [<a href="/pubmed/14571732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14571732</span></a>]<div><i>(58 year old woman 9 years after lung transplant for alpha-1-antitrypsin deficiency on multiple medications including prochlorperazine for 27 months developed jaundice and chronic allograft rejection [peak bilirubin 38.6 m/dL, ALT 71 U/L, Alk P 362 U/L]; drug stopped, but only 3 days of follow up provided).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, none were due to phenothiazines).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury including 4 due to psychotropic agents; one each for quetiapine, nefazodone, fluoxetine and venlafaxine, but none to phenothiazines).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.molleston.2011.182">Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N., Drug-induced Liver Injury Network.  Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>2011;<span class="ref-vol">53</span>:182–9.</span> [<a href="/pmc/articles/PMC3634369/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3634369</span></a>] [<a href="/pubmed/21788760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21788760</span></a>]<div><i>(Among 30 children with suspected drug induced liver injury, half [n=15] were due to antimicrobials [minocycline 4, INH 3, azithromycin 3] and the rest largely due to CNS agents and anticonvulsants; one case was attributed to perphenazine but none to prochlorperazine).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.marwick.2012.244">Marwick KF, Taylor M, Walker SW. Antipsychotics and abnormal liver function tests: systematic review. <span><span class="ref-journal">Clin Neuropharmacol. </span>2012;<span class="ref-vol">35</span>:244–53.</span> [<a href="/pubmed/22986798" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22986798</span></a>]<div><i>(Systematic review of the literature found rates of any serum enzyme elevation during antipsychotic therapy to range from 5-78% and "clinically significant' elevations in 0-15%; lists 12 reports of clinically apparent liver injury due to prochlorperazine, one of which was fatal [McFarland 1963]).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, only one of which was attributed to chlorpromazine, the only antipsychotic medication listed).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 5 cases [0.6%] were attributed to antipsychotic agents, including 3 due to quetiapine and 2 to olanzapine, but none to prochlorperazine or other phenothiazines]).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF32">Drugs for psychotic disorders. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2016;<span class="ref-vol">58</span>(1510):160–4.</span> [<a href="/pubmed/27960194" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27960194</span></a>]<div><i>(Concise review of medications available in the US for therapy of psychotic disorders; the phenothiazines are discussed but not prochlorperazine).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.schreiner.2017.339">Schreiner NM, Windham S, Barker A. Atypical neuroleptic malignant syndrome: diagnosis and proposal for an expanded treatment algorithm: a case report. <span><span class="ref-journal">A A Case Rep. </span>2017;<span class="ref-vol">9</span>:339–43.</span> [<a href="/pubmed/28767476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28767476</span></a>]<div><i>(48 year old man with bipolar disorder and NASH underwent liver transplantation and developed confusion, dyskinesia, rigidity, hyperthermia and tachycardia/tachypnea postoperatively having been given lithium, lamotrigine, promethazine and ziprasidone, responding to therapy of neuroleptic malignant syndrome with benzodiazepines and propofol).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.baeza.2018.463">Baeza I, de la Serna E, Calvo-Escalona R, Merch&#x000e1;n-Naranjo J, Rodr&#x000ed;guez-Latorre P, Mart&#x000ed;nez-Cantarero MC, Andr&#x000e9;s P, et al.  One-year prospective study of liver function tests in children and adolescents on second-generation antipsychotics: is there a link with metabolic syndrome? <span><span class="ref-journal">J Child Adolesc Psychopharmacol. </span>2018;<span class="ref-vol">28</span>:463–73.</span> [<a href="/pubmed/29975563" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29975563</span></a>]<div><i>(Among 216 children and adolescents starting atypical antipsychotics, mean weight gain at 6 months was 6.5 kg and mean ALT levels increased by 8.6 U/L, while among 37 taking olanzapine mean weight gain was 10.3 kg and ALT increase 2.6 U/L; increases in ALT associated with development of the metabolic syndrome, mean ALT increasing by 27.8 U/L at 6 months).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.ouellette.2019.1982">Ouellette L, Judge B, Zamarripa A, McFadden P, Jones J. Safety and effectiveness of intravenous prochlorperazine for intractable vomiting in children with gastroenteritis. <span><span class="ref-journal">Am J Emerg Med. </span>2019;<span class="ref-vol">37</span>:1982–3.</span> [<a href="/pubmed/31005395" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31005395</span></a>]<div><i>(Among 390 children with acute gastroenteritis given a single infusion of prochlorperazine, 92% had relief of nausea within 3 hours and only 24 [6%] required a second dose; adverse reactions included akathisia/dystonia in 3% to 4%, no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.golikhatir.2019.682">Golikhatir I, Cheraghmakani H, Bozorgi F, Jahanian F, Sazgar M, Montazer SH. The efficacy and safety of prochlorperazine in patients with acute migraine: a systematic review and meta-analysis. <span><span class="ref-journal">Headache. </span>2019;<span class="ref-vol">59</span>:682–700.</span> [<a href="/pubmed/30990883" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30990883</span></a>]<div><i>(In a systematic review of 11 controlled trials in patients with migraine headaches, prochlorperazine was more effective than placebo and other comparators, and adverse events included akathisia, dystonia, drowsiness and orthostatic hypotension; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Prochlorperazine.REF.haldipur.2020.61">Haldipur D, Krishnamurthy N, A B. The real-world safety and effectiveness of prochlorperazine in Indian patients with dizziness. <span><span class="ref-journal">J Assoc Physicians India. </span>2020;<span class="ref-vol">68</span>:61–6.</span> [<a href="/pubmed/32009365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32009365</span></a>]<div><i>(Among 500 patients treated with prochlorperazine [5 mg three times daily for 7 days], dizziness improved in most and only three patients reported adverse events: somnolence, headache and fatigue).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548122</span><span class="label">PMID: <a href="/pubmed/31643452" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643452</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Procarbazine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Progestins/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548122&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548122/?report=reader">PubReader</a></li><li><a href="/books/NBK548122/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548122" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548122" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Prochlorperazine. [Updated 2020 Jul 1].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548122/pdf/Bookshelf_NBK548122.pdf">PDF version of this page</a> (128K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Prochlorperazine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Prochlorperazine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Prochlorperazine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Prochlorperazine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4862976" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4862976" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4862976" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/2000539" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Acute oculogyric crisis after administration of prochlorperazine.</a><span class="source">[South Med J. 1991]</span><div class="brieflinkpop offscreen_noflow">Acute oculogyric crisis after administration of prochlorperazine.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schumock GT, Martinez E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">South Med J. 1991 Mar; 84(3):407-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/13570840" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Complications following the use of prochlorperazine (compazine) as an antiemetic.</a><span class="source">[AMA J Dis Child. 1958]</span><div class="brieflinkpop offscreen_noflow">Complications following the use of prochlorperazine (compazine) as an antiemetic.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">CLEVELAND WW, SMITH GF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">AMA J Dis Child. 1958 Sep; 96(3):284-7. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/13497437" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Prochlorperazine as an antiemetic in the severely retarded child.</a><span class="source">[AMA J Dis Child. 1958]</span><div class="brieflinkpop offscreen_noflow">Prochlorperazine as an antiemetic in the severely retarded child.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">BERMAN HH, LAZAR M, NOE O. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">AMA J Dis Child. 1958 Feb; 95(2):146-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643669" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Thioridazine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Thioridazine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21425885" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache.</a><span class="source">[CNS Drugs. 2011]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hoy SM, Scott LJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">CNS Drugs. 2011 Apr; 25(4):343-58. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643452" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643452" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604690069e31203af6b8c97d">Prochlorperazine - LiverTox</a><div class="ralinkpop offscreen_noflow">Prochlorperazine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:58:47-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal101&amp;ncbi_phid=CE886A8B046733B100000000069701E0&amp;ncbi_session=CE886A8B04690051_1687SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548122%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548122&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548122/&amp;ncbi_pagename=Prochlorperazine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE886A8B04690051_1687SID /projects/books/PBooks@9.2 portal101 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>